🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

23 recruiting trials

for Metastatic Endocrine Refractory

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma NCT07189195Phase 11 site📍 Sacramento University of California, Davis · Tests: TR-002 Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer NCT06030622Phase 1, Phase 21 site📍 Brooklyn State University of New York - Downstate Medical Center · Tests: Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin), C3 (Metformin, Simvastatin, and Digoxin) only IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors NCT06785077NA1 site📍 Milan European Institute of Oncology · Tests: buccal cells, bone marrow cells, peripheral blood cells, bone marrow biopsy Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors NCT05053971Phase 1, Phase 23 sites📍 New Haven📍 Gainesville📍 Oklahoma City National Cancer Institute (NCI) · Tests: BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy, Entinostat Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer NCT06970353Phase 21 site📍 Shanghai Fudan University · Tests: Tunlametinib, Tunlametinib+PD-1 mAb Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer NCT03099356Phase 21 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Cyclophosphamide, Sirolimus A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer NCT07205822Phase 340 sites📍 Largo📍 Fort Wayne📍 Omaha AstraZeneca · Tests: Dato-DXd XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer NCT06959641Phase 22 sites📍 Torrance📍 Chicago Jochen Lorch · Tests: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Survey Administration, X-Ray Imaging Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC NCT05668962Phase 26 sites📍 Washington D.C.📍 Tampa📍 Boston Massachusetts General Hospital · Tests: Selpercatinib, Sodium Iodine I-131, rhTSH 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871Phase 1, Phase 25 sites📍 Dothan📍 Grand Rapids📍 Omaha Radiopharm Theranostics, Ltd · Tests: 177Lu-BetaBart, BetaBart + unlabeled BetaBart Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma NCT05994365n/a3 sites📍 Beijing📍 Tianjin📍 Tianjin Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: Anlotinib Hydrochloride Capsule A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors NCT07029399Phase 118 sites📍 Duarte📍 La Jolla📍 Denver NiKang Therapeutics, Inc. · Tests: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors NCT04119024Phase 13 sites📍 Duarte📍 Los Angeles📍 Stanford Anusha Kalbasi · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NCT07182149Phase 118 sites📍 Denver📍 New Haven📍 Washington D.C. Normunity AccelCo, Inc. · Tests: NRM-823 A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187Phase 110 sites📍 Denver📍 Orlando📍 Sarasota Dren Bio · Tests: DR-0202 A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma NCT06860971Phase 335 sites📍 Hefei📍 Beijing📍 Chongqing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: AL2846 Capsules, AL2846 Placebo A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma NCT07229417Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Ivonescimab A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957Phase 120 sites📍 Little Rock📍 Los Angeles📍 San Francisco NiKang Therapeutics, Inc. · Tests: NKT3964, Paclitaxel, Doxorubicin Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer NCT06799065Phase 1, Phase 211 sites📍 Aurora📍 Sarasota📍 Detroit Accent Therapeutics · Tests: ATX-295, ATX-295 and bevacizumab (or biosimilar)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy